Table 3.
Effect of topical application of antagonist
| Series | MABP (mmHg) | HR (beats min−1) | CoRCF (% baseline) | CoVC (% baseline) | CBF (% baseline) | CVC (% baseline) | |
|---|---|---|---|---|---|---|---|
| 1 | Control | 108 ± 6 | 382 ± 17 | 100 | 100 | 100 | 100 |
| + 8-PT | 106 ± 6 | 391 ± 17 | 111 ± 7 | 118 ± 6 | 100 ± 5 | 102 ± 5 | |
| 2 | Control | 117 ± 4 | 425 ± 14 | 100 | 100 | — | — |
| + 8-SPT | 117 ± 5 | 420 ± 16 | 94 ± 5 | 91 ± 8 | — | — | |
| 4 | Control | 126 ± 5 | 387 ± 11 | 100 | 100 | — | — |
| + ZM241385 | 125 ± 5 | 377 ± 11 | 96 ± 6 | 98 ± 5 |
Effect of topical application of antagonist in Series 1 (8-PT), Series 2 (8-SPT) or Series 4 (ZM241385) on baseline values of the measured variables.